Holen Sie sich die Stockscreener-App
51.21
1.11%
0.56
Vorhandelsmarkt:
51.17
-0.04
-0.08%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$50.65
Offen:
$50.79
24-Stunden-Volumen:
12.11M
Relative Volume:
0.75
Marktkapitalisierung:
$104.25B
Einnahmen:
$48.03B
Nettoeinkommen (Verlust:
$6.05B
KGV:
17.29
EPS:
2.9615
Netto-Cashflow:
$15.30B
1W Leistung:
+0.49%
1M Leistung:
+8.36%
6M Leistung:
+2.48%
1J Leistung:
-11.89%
1-Tages-Spanne:
$50.33
$51.61
1-Wochen-Bereich:
$50.23
$52.51
52-Wochen-Spanne:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Vergleichen Sie BMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
51.21 | 103.11B | 48.03B | 6.05B | 15.30B | 2.9615 |
|
LLY
Lilly Eli Co
|
993.64 | 879.11B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
206.54 | 481.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
225.18 | 394.11B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
131.19 | 251.38B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
97.62 | 240.48B | 63.90B | 19.05B | 13.05B | 7.5596 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Bristol-Myers Squibb’s Strategic Moves: A Dual Focus on Shareholder Returns and Oncology Expansion - Ad-hoc-news.de
Bristol Myers (BMY) Declares Increased Quarterly Dividend for 20 - GuruFocus
Bristol Myers Squibb raises quarterly dividend by 1.6% - Investing.com India
Bristol-Myers Squibb Raises Quarterly Dividend by 1.6% to $0.63 a Share, Payable on Feb. 2, 2026 to Shareholders of Record on Jan. 2, 2026 - marketscreener.com
Bristol Myers Squibb Announces Dividend Increase - marketscreener.com
Wells Fargo Raises Price Target for Bristol-Myers Squibb (BMY) t - GuruFocus
BioNTech and BMS’ bispecific touts 59.3% nine-month PFS in TNBC - Yahoo
Jefferies Remains Bullish on Bristol-Myers Squibb Company (BMY) - Insider Monkey
Crohn’s Disease Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | AbbVie, Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH - Barchart.com
HSBC Adjusts Price Target on Bristol-Myers Squibb to $53 From $50, Maintains Hold Rating - marketscreener.com
Bristol Myers Squibb (BMY): Revisiting Valuation After a Recent Share Price Rebound - Yahoo Finance UK
BioNTech And Bristol’s Pumitamig Is Encouraging In Triple-Negative Breast Cancer - Citeline News & Insights
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options - Benzinga
Bristol Myers Squibb Company $BMY Shares Bought by Investment Management Corp of Ontario - MarketBeat
BioNTech, Bristol Myers presents Phase 2 data for PD-L1xVEGF-A - TipRanks
66,361 Shares in Bristol Myers Squibb Company $BMY Bought by SVB Wealth LLC - MarketBeat
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer - The Manila Times
Bristol Myers Squibb Company $BMY Stock Position Raised by Axa S.A. - MarketBeat
Analysts Project Modest Upside To Bristol-Myers Squibb Company (BMY) - Insider Monkey
Bristol Myers Squibb (BMY) Is Up 5.1% After Expanded Breyanzi MZL Approval Has The Bull Case Changed? - simplywall.st
Bristol Myers Squibb showcases new lymphoma therapy data at ASH meeting - Investing.com Canada
Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025 - Yahoo Finance
Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business? - Yahoo Finance
Leerink Maintains Outperform Rating as Bristol Myers (BMY) Expands ADEPT-2 Enrollment - Yahoo Finance
Bristol Myers Squibb a Top 25 Dividend Giant With 4.76% Yield (BMY) - Nasdaq
Bristol-Myers Squibb Stock Gains Momentum from Key Regulatory Approval - AD HOC NEWS
14 Best US Stocks to Buy for Long Term - Insider Monkey
Antibody Discovery Market to Reach USD 17.68 Billion by 2032, Driven by Rising Demand for Targeted Therapies and Advancements in AI Powered Antibody Engineering – SNS Insider - GlobeNewswire Inc.
California Public Employees Retirement System Has $286.27 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Cresset Asset Management LLC Decreases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Epoch Investment Partners Inc. - MarketBeat
Bristol-Myers Squibb Just Got Crucial FDA Backing On Alzheimer’s Psychosis Program; What's NEXT? - Smartkarma
Jim Cramer on Bristol-Myers' Recent Stock Gain: "Unbelievable" - Finviz
Jim Cramer on Bristol-Myers’ Recent Stock Gain: “Unbelievable” - Insider Monkey
Bristol-Myers Squibb Co (BMY) Stock Price, Trades & News - GuruFocus
Do These 3 Healthcare Stocks Need a Checkup? - Finviz
What's Going On With Bristol-Myers Squibb Stock Friday?Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Praxis soars higher; Bristol Myers’ CAR-T therapy wins broader use - Yahoo Finance
First Trust Advisors LP Has $212.59 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) – Company AnnouncementFT.com - Financial Times
DEERFIELD MANAGEMENT COMPANY, L.P.'s Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Rx Rundown: Bristol Myers Squibb, Retro Bio, Ionis Pharmaceuticals and more - Medical Marketing and Media
Water stewardship for environmental sustainability - Bristol Myers Squibb
How risky is Bristol Myers Squibb Company stock compared to peers2025 Market WrapUp & Free Risk Controlled Daily Trade Plans - Newser
Bristol Myers Pushes Data Readout For Key Alzheimer's Psychosis Study After Irregularities - Sahm
BMY Gains on News of Continuation of Alzheimer's Disease Study - Finviz
Florida key to BMS slip in ADP? Acadia sails ahead - BioWorld MedTech
Scotiabank raises Bristol-Myers Squibb stock price target to $53 on pipeline - Investing.com Nigeria
Invesco Ltd. Raises Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
CW Advisors LLC Increases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):